biopharm, which is supported by the fact they kept Sunrise open till the beginning of this year.
Several entities now begin to report (and we just saw one yesterday I believe) that patients that have been PREVIOUSLY treated with Bavituximab as part of the Sunrise clinical trial do have benefits of that in a NEXT treatment compared to those that didn't get it.
That comes also back to the lasting effect. The immune response of which we talked. And that is all due to Fx-gamma AND PtdSer binding by the Bavituximab molecule.
Blocking immune suppression alone is INSUFFICIENT. One must at the same time Stimulate the Immune system to activate, otherwise no immune learning will take place and no LASTING effect will be detected.
AND you CANNOT do that when you bind PS-receptors because there are on the SAME cell as the Fx-Gamma receptors (e.g. on MDSCs, M2-Macrophages and immature dendretic cells). So you'dd need a separate molecule for that or a PS binding molecule that bends as a U to bind two receptors (PS & Fx) but that would ONLY be possible if they would always have fixed distances between each other and be in reasonable distance AND the same on each cell type.
That is where the value of the PPHM IP and pipeline portfolio is. It has been sufficiently proven to BP that it works EVEN if not FDA approved because of control arm anomalies nothing to do with PPHM.
AIMO
Market Data 
Markets 
AI
